Moderna has now rallied 68% in a month to $79.77 — yet the Street's price targets remain well below the current price, and 15.6% of the free float is still short.
The analyst picture this week captures the tension neatly. Three firms lifted targets in the past two days, but none of them turned bullish. Morgan Stanley raised to $39 from $33 while holding Equal-Weight. RBC moved to $45 from $38, keeping Sector Perform. Bank of America went to $38 from $34, staying Underperform. Even Piper Sandler, the most constructive name in the coverage, only got to $77 with its raise last month — still below where the stock closed Tuesday. The consensus mean target sits at $47.89, roughly 40% below the current price. The Street is acknowledging the move, not endorsing it.
Options positioning has turned sharply more defensive, adding another layer of tension. The put/call ratio hit 1.01 on July 7 — nearly 2.4 standard deviations above its 20-day average of 0.92. That's the most pronounced defensive lean in options in months, and it arrived precisely as the stock touched new multi-year highs. For context, the 52-week high on the PCR is 1.18, so the current level is elevated but not at maximum fear. The move suggests a meaningful cohort of options traders is paying for downside protection rather than chasing the rally with calls.
Short positioning has barely shifted from what the previous two notes described, but the direction of travel is worth tracking. Short interest nudged up to 15.6% of the free float on July 7, fractionally above the 15.4% reading from July 1 that was itself a slight reduction from the 16.33% peak in late June. Roughly 61 million shares remain borrowed — essentially the same position that was held when the stock was at $47. The lending market offers no squeeze pressure: availability is comfortable at 241%, well above the 52-week floor of 196%, and cost to borrow fell sharply this week to 0.46%, down nearly 24% over seven days. Shorts are holding firm, but they're doing so cheaply and with ample room for others to join them. Days-to-cover on the official FINRA data remains at 10.5 — any forced unwind would clear slowly.
The ownership picture adds one note of interest. FMR (Fidelity) added 17.6 million shares in the most recent filing, lifting its stake to 11.5% — the largest single institutional holder and a meaningful accumulation. Capital Research also added nearly 5.9 million shares. That institutional buying sits in direct contrast to insider activity: the CFO sold a small parcel on July 2 following tax-related sales in June, and President Stephen Hoge sold 53,000 shares at $51.37 in mid-June — at prices well below the current level. Those insider sales look mechanical rather than strategic given the timing, but they add to a picture where insiders at recent prices were not buyers.
With Q2 earnings confirmed for August 6, the next few weeks bring the clearest test of whether the rally has fundamental backing. The prior two earnings releases produced 1-day gains of roughly 3-4% each, with five-day follow-through of 8-18%. The question heading into August is whether the stock can sustain a valuation — currently price-to-book near 5x, with earnings still negative — that has run well past where even the most constructive analysts have set their targets.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
